← Back to Search

Gamma Secretase Inhibitor

Nirogacestat for Aggressive Fibromatosis (DeFi Trial)

Phase 3

Waitlist Available

Led By Bernd Kasper, MD

Research Sponsored by SpringWorks Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up daily for the last 7 days of every cycle (each cycle is 28 days) through study completion, an average of 2 years

Awards & highlights

DeFi Trial Summary

This trial will evaluate if nirogacestat is effective in treating desmoid tumor/aggressive fibromatosis. Half the participants will receive nirogacestat, the other half placebo, in the double-blind phase. All participants will receive nirogacestat in the open-label phase.

Who is the study for?

This trial is for adults with a type of tumor called desmoid tumor/aggressive fibromatosis (DT/AF) that has grown by at least 20% in the past year. Candidates must have finished any previous treatments for DT/AF at least 28 days before starting the study and resolved all treatment side effects to mild levels. They should be able to perform daily activities with slight limitations or better, as assessed by their ECOG performance status.Check my eligibility

What is being tested?

The trial is testing nirogacestat, an oral tablet, against a placebo (a pill without active medication). Participants are randomly assigned to one of these two groups in a double-blind phase where neither they nor the researchers know who's receiving which treatment. After this phase, all participants will receive nirogacestat during an open-label phase.See study design

What are the potential side effects?

While specific side effects for nirogacestat aren't listed here, common types of side effects from medications like it may include digestive issues, fatigue, skin reactions, changes in liver function tests and potentially increased risk of infections.

DeFi Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ daily for the last 7 days of every cycle (each cycle is 28 days) through study completion, an average of 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~daily for the last 7 days of every cycle (each cycle is 28 days) through study completion, an average of 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and daily for the last 7 days of every cycle (each cycle is 28 days) through study completion, an average of 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of progression free survival (PFS) events as defined as the time from randomization until date of assessment of progression or death by any cause.

Secondary outcome measures

Change from baseline in PRO scores using the Brief Pain Inventory (BPI) short form.

Change from baseline in PRO scores using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC) QLQ-C30.

Change from baseline in PRO scores using the GOunder/Desmoid Tumor Research Tumor Foundation (DTRF) DEsmoid Impact Scale (GODDESS);

+6 more

DeFi Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: Open-Label Phase - NirogacestatExperimental Treatment1 Intervention

Nirogacestat 150 mg by mouth, twice daily

Group II: Double-Blind Phase - NirogacestatExperimental Treatment1 Intervention

Nirogacestat 150 mg by mouth, twice daily

Group III: Double-Blind Phase - PlaceboPlacebo Group1 Intervention

Placebo 150 mg by mouth, twice daily

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

SpringWorks Therapeutics, Inc.Lead Sponsor

12 Previous Clinical Trials

824 Total Patients Enrolled

Bernd Kasper, MDPrincipal InvestigatorMannheim University Medical Center

1 Previous Clinical Trials

52 Total Patients Enrolled

Media Library

Nirogacestat (Gamma Secretase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03785964 — Phase 3

Aggressive Fibromatosis Research Study Groups: Double-Blind Phase - Placebo, Double-Blind Phase - Nirogacestat, Open-Label Phase - Nirogacestat

Aggressive Fibromatosis Clinical Trial 2023: Nirogacestat Highlights & Side Effects. Trial Name: NCT03785964 — Phase 3

Nirogacestat (Gamma Secretase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03785964 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you please provide more information on the risks associated with Nirogacestat oral tablet?

"Given that this is a Phase 3 trial with evidence of efficacy and safety from multiple rounds of data, our team at Power rates the Nirogacestat oral tablet a 3 for safety."

Answered by AI

In how many medical facilities is this clinical trial being conducted?

"Currently, this clinical trial has 36 patients enrolled. A few notable locations where patients are receiving treatment are DUMC/Duke Cancer Center in Durham, Henry-Joyce Cancer Clinic in Nashville, and UT Southwestern Medical Center in Dallas."

Answered by AI

Is Nirogacestat oral tablet a new medication?

"First studied in 2013 at the National Institutes of Health Clinical Center, Nirogacestat has had 169 completed clinical trials as of now. Out of the 8 clinical trials that are presently active, a majority of them are based in Durham, North carolina."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

2019. "Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03785964.